joining us live now is the author of that article, standard business reporter kevin truong. retty well. i mean, let's see how san francisco's doing. mayor breed has declared the city the ai capital of the world. so is ai the answer to filling those empty office buildings? >> well, ai is part of the answer. the problem is ai is so early stage right now, although we're seeing, you know, blue chip brand names almost develop within the industry companies like openai, anthropic scale ai, and they're all happen to be based in san francisco. the problem is with a lot of the tech companies that departed san francisco's downtown and office centers, those took years to develop. and right now we're just seeing ai at the very beginning. so it's just a little bit of a matter of scale at this point. got it. >> but it's got potential. it's going to grow and right now, two of those brand names you talked about in the industry, openai and i think anthropic are getting big leases in the city. talk about that. where are they going to be? >> right. so anthropic, which is bills itself as a kind o

we've had julie zagorz and kevin truong on before. lively conversation. how can people take part? >> and just go to our website at substandard.com and you can register for free right there. >> all right. julie mckinnon, editor in chief of the standard. thank you so much. >> thank you. >> and a reminder once again, that series of live free q&a sessions launching this thursday. join a rotating cast of editors and reporters who will share their insights and answer your questions on subjects ranging from the real estate market to robo taxis behaving badly or people behaving badly in robo taxis. the series kicks off thursday at noon with a deep dive on the future of downtown san francisco. as julie mentioned, registration is free and again, that's at the standard's website . sf standard.com. we'll take a short break thousands of women with metastatic breast cancer, are living in the moment and taking ibrance. ibrance with an aromatase inhibitor is for adults with hr+/her2- metastatic breast cancer as the first hormonal based therapy. ibran